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Abstract
In this paper we develop a Bayesian statistical inference approach to the
unified analysis of isobaric labelled MS/MS proteomic data across multiple
experiments. An explicit probabilistic model of the log-intensity of the iso-
baric labels’ reporter ions across multiple pre-defined groups and experiments
is developed. This is then used to develop a full Bayesian statistical methodol-
ogy for the identification of differentially expressed proteins, with respect to a
control group, across multiple groups and experiments. This methodology is
implemented and then evaluated on simulated data and on two model exper-
imental datasets (for which the differentially expressed proteins are known)
that use a TMT labelling protocol.
Keywords: proteomics, Bayesian, mass spectrometry, MS/MS, differential
protein expression
1 Introduction
In recent years, isobaric molecular labelling techniques have been developed which,
in conjunction with tandem mass spectrometry (also known as MS/MS), can be used
to perform quantitative analyses of complex protein mixtures (Thompson et al.,
2003; Ross et al., 2004). This procedure involves using enzymes such as trypsin to
digest the proteins in the samples into their constituent peptides. Isobaric molecular
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labels (one label per sample) are then chemically attached to the resulting peptide
components of the enzyme digested proteins. The samples are then mixed and
passed through a liquid chromatograph into a mass spectrometer where tandem
mass spectrometry is performed. The relative intensities of these labels for the
resulting MS/MS spectra can be determined from the intensities of the isobaric
labels’ “reporter” ions. The MS/MS spectra are those of the constituent peptides
and these can be identified either by hand or, more usually, using a protein sequence
database. If the identified peptides are prototyped for a protein, i.e. peptides that
can be uniquely derived from the digestion of a protein, then the relative amounts
of this protein in the labelled samples can be quantified.
The experimental process described above is inherently stochastic as even
technically identical replicates will produce different data regardless of the accuracy
of the mass spectrometer. Also there is a wide “dynamic” range in the intensity of
the detected peptides. This matters because only a limited number of ions can
be subject to MS/MS. The highest intensity ions are the ones which tend to be
selected. As such, the more abundant proteins, especially large proteins, will tend
to drown out less abundant smaller proteins. A variety of techniques exist by which
the complex protein mixture can be split up into simpler fractions but these do not
completely eliminate the problem. An additional problem is that there are a limited
number of isobaric tags available. The maximum currently commercially available
is eight (Choe et al., 2007). This limits the number of samples that can be analyzed
in a single experiment. However, it should be possible to analyze a larger number of
samples using multiple experiments that, for example, share a common reference
sample. This requires that any analysis technique used be able to link data from
multiple experiments of this type.
Apart from the peptide identification problem (Befekadu et al., 2009), the
main statistical problem in analysing MS/MS data is how to detect which of the
proteins in a complex mixture are present in significantly different amounts in a
set of isobaric labelled samples from two or more pre-determined groups such as
a control group and a set of treatment groups. Currently standard software such
as MASCOT (Perkins et al., 1999) is quite limited as they attempt to detect differ-
ences between two groups either by a informal thresholding on the fold-ratio or by
using a t-test, which in turn can be generalised to a comparison of more groups via
a one-way ANOVA. The t-test method typically makes the reasonable assumption
that the intensities of the reporter ions for MS/MS spectra of proteotypic peptides
are log-normally distributed (Boehm et al., 2007). However, using the t-test ap-
proach has several drawbacks. The main problem arises from having to test a large
number of hypotheses to determine significant differences in expression levels be-
tween groups, as a test is needed for each of the hundreds of proteins. Of course,
such problems can be somewhat mitigated by using standard multiple hypotheses
corrections (Sidak, 1968; Holm, 1979; Benjamini and Hochberg, 1995). Another
problem with using t-test is that many suffer from low power due to proteins being
quantified on the basis of only a small number of MS/MS spectra.
To circumvent these issues, various authors have developed methods using
a more detailed model for the peptide intensity and use ANOVA analytic techniques
to determine differences between protein expression levels for different groups and
their associated statistical significance. Keshamouni et al. (2006) describe a very
simple ANOVA model for normalised log-ratios in a single experiment compar-
ing a single treatment against a control. A more sophisticated ANOVA model for
multiple treatments and experiments is described in Oberg et al. (2008). Although
their full model is somewhat overparameterised, it is easily reduced to an identifi-
able model by combining some parameters and setting others to zero. This reduced
model is very closely related to the model described in this paper. The main inno-
vations introduced here are that the model is fit jointly to all of the data simultane-
ously, rather than using a stepwise regression approach, that the fitting is done in
a fully Bayesian way, and that the Bayesian version of the model includes variable
selection indicators for differential expression, allowing direct inference to be made
for the probability of differential expression associated with each protein. Note that
related methods for LC–MS data are often tailored to specific features of that data.
For example, the models of Karpievitch et al. (2009) and Wang et al. (2012) are
tailored to a specific kind of informative missingness in the data which does not
arise for isobaric labelled MS/MS data. In the MS/MS framework considered here,
missingness is generally much less of an issue than for LC–MS data (Oberg and Ma-
honey, 2012), and there is little evidence to suggest that missing values in MS/MS
data sets are strongly informative. Nevertheless, as for all proteomics technologies,
there is still an issue with certain peptides not being detected at all during the first
phase of the MS/MS procedure. Our model deals correctly with such missingness,
in a fairly efficient way.
In this paper we fit a detailed random effects model with an ANOVA form to
analyse protein expression levels, but remove or consolidate many of the parameters
that Oberg et al. (2008) find to be typically confounded. The model is a hierarchi-
cal model which borrows strength appropriately across multiple peptides, proteins,
samples and experiments. Unlike the stepwise regression approach described by
Oberg et al. (2008), our fitting approach does not force each protein to have an in-
dependent variance parameter, and correctly propagates normalisation uncertainty
without assuming approximate orthogonality of model components. In common
with Oberg et al. (2008), our model allows for the analysis of multiple experiments
with common reference samples. Additionally, our method adopts a fully Bayesian
approach and therefore has all the advantages of interpretability and being able to
include prior information (where available). The Bayesian approach also has sev-
eral advantages specific to the context of complex hierarchical models. The frame-
work is flexible, and allows convenient checking for over-parametrisation or vari-
able confounding by prior to posterior comparisons and multi-dimensional analysis
of the posterior distribution. Importantly the model has a variable selection form
which ensures that we fit an appropriate model for the combination of differentially
expressed and non-differentially expressed proteins. Models without this structure
have the drawback that they inflate the error variance in the “null” model due to
contamination by outlying differentially expressed proteins which then hinders the
detection of differential expression.
In the next section we give more details of the experimental framework and
describe the model together with the prior-to-posterior analysis. In section 3 we
demonstrate the potential of the model to pool information across multiple MS/MS
experiments by using simulated data. In sections 4 and 5 we analyse two real
MS/MS datasets. The real datasets have a simple structure but serve to demonstrate
that our model captures the behaviour of real experimental data. The dataset in
section 4 has two technically identical replicates and so contains a negative control,
that is, there should be no differentially expressed proteins. The dataset in section 5
is provided by the ProteoRed consortium as part of an assessment of various quan-
titative proteomics methods. It contains known differentially expressed proteins
within an otherwise set of technically identical replicates. The paper concludes in
section 6 with a discussion.
2 Methods
2.1 Experimental framework
The experimental framework of an isobaric labelled MS/MS experiment is as fol-
lows: the protein samples, each containing roughly equal amounts of total protein
by mass, are digested using enzymes with typically high specificity such as trypsin
i.e. they cleave the protein molecules into peptide fragments at predictable amino
acid residues. The digested samples are then each chemically labelled with different
isobaric labelling molecules. The samples are then mixed together and run through
a liquid chromatograph into a mass spectrometer.
A selection of high intensity ions from the resulting MS spectra are then
shattered, using high energy collisions, to yield further ion spectra called MS/MS
spectra. The chemically attached molecules leave signature or reporter ions in the
MS/MS spectra. The relative intensity of these reporter ions will give us relative
quantitative information about the amounts of the peptide fragments, corresponding
to each MS/MS spectra, in each sample.
The above constitutes a single experiment. Multiple experiments (E) can of
course be performed either with technical or biological sample replicates. The sam-
ples being analyzed are typically assigned to pre-determined biological groups. For
simplicity, only the MS/MS spectra corresponding to peptide fragments uniquely
derived from a single protein are used in the quantitative analysis. This means that
a single MS/MS spectrum gives quantitation information about a single protein.
Thus we need a model that will simultaneously model the observed expression lev-
els for P proteins for the G biological groups to which the samples being analyzed
are assigned. One of the biological groups is used as the control group. Differ-
ences in protein expression level are then measured relative to this control. The
total protein content of each sample that ends up being labelled are only roughly
equal. In our model we include a parameter which allows for differing amounts of
total labelled samples in an experiment. In addition, when performing the analysis
across multiple experiments it is important to be able to “link” the experiments. In
order to facilitate this a reference sample is selected in each experiment. Ideally
this should be a technical replicate of some standard sample that is included in all
our experiments.
An example of an experimental design is given in Figure 1. It shows a sce-
nario with two experiments for twelve samples from four groups with three replicate
samples per group assuming that only six isobaric labels are available for any single
experiment.
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Figure 1: Schematic of an experimental design for twelve samples from four groups
(three replicate samples per group) using six available isobaric labels (A-F).
2.2 The Model
We consider a series of isobaric labelled mass spectrometric experiments designed
using nI distinctly identifiable isobaric tags (we will typically have nI = 6). We
assume that for each experiment e, we have (log) intensity measurements yegjki in
treatment group g arranged by sample/replicate number i from an MS/MS spec-
trum k identified as being that of a peptide derived from a protein j. Specific pep-
tides are therefore identified by a particular (j, k) combination. The isobaric tags
are used to identify the (g, i) combinations within an experiment. The model has
an ANOVA style, starting with a sample-specific normalising constant, κegi, and
then decomposing the remaining uncertainty using a variable selection approach in
the style of Kuo and Mallick (1998); see O’Hara and Sillanpaa (2009) for a review
of other possible approaches. The benefits of Bayesian hierarchical modelling in
the context of gene expression microarrays is already well established (Hein et al.,
2005). Explicit inclusion of the normalisation constant in the model ensures that
important information in the data is not lost during the normalisation process (Hein
et al., 2005; Karpievitch et al., 2012; Callister et al., 2006; Hill et al., 2008). The
benefits of including the normalising constant directly in ANOVA–style fixed and
random effects models for proteomics data is most clearly articulated in Oberg et al.
(2008), to which the reader is referred for further details.
We model the log intensities as
yegjki = κegi + αjk + βgjγgj + ǫegjki, (1)
e = 1, . . . , E, g = 1, . . . , G, j = 1, . . . , P , k = 1, . . . , mj and i = 1, . . . , neg,
where, for identifiability, the parameters are subject to the constraints
β1j = γ1j = 0, j = 1, . . . , P and κege1 = 0, e = 1, . . . , E,
where ge is the group in experiment e whose first sample is used as the reference
sample. In general, differential expression will be measured against a control group
and this group will be labelled group 1. The control group will commonly also
provide a reference sample in each experiment (giving ge = 1), though sometimes
the experimenter might choose different groups to provide the reference samples.
Thus the number of isobaric labels used in each experiment is
∑
g neg = nI . Note
that a MS/MS spectrum is assumed to be “assigned” to one and only one protein.
In a typical experiment some reporter ions do not show up in a particular
MS/MS spectrum. This corresponds to missing data in the model and can be dealt
with by treating these unobserved values in the usual Bayesian MCMC way, that is,
by including the missing data in the model as unobserved parameters and stochas-
tically imputing them along with all other unknowns. This leads to the correct pos-
terior distribution (which is less concentrated than it would have been in the case
of full observation), but at the expense of poorer mixing of the MCMC scheme.
However, a more efficient implementation is possible by using a “ragged array”
with varying dimension indices, which avoids creating variables corresponding to
the missing data. We adopt this latter scheme in the implementation we describe
in section 2.3.2, as it has significantly better mixing properties than the naive ap-
proach.
The interpretation of the parameters is as follows. The parameters κegi are
normalization constants for sample i in group g of experiment e relative to the
reference sample in that experiment, that is, the log-ratio of the total amount of
sample i (in group g of experiment e) with respect to the reference sample (sample 1
in group ge of experiment e). The αjk parameters are the mean log-intensities of
a peptide k (corresponding to a reporter ion in an MS/MS spectrum) assigned to
protein j for labelled samples from (control) group 1. The βgj parameters are binary
indicating whether or not the protein j is differentially expressed for biological
group g with respect to (control) group 1 and the γgj parameters are the difference
in the mean log-expression level of protein j between group g and (control) group 1.
Finally, the ǫegjki are independent and identically distributed noise terms following
a normal N(0, σ2) distribution with zero mean and variance σ2.
2.3 Bayesian Inference
The inference task is to make statistically valid statements about the unknown
model parameters (κ,α,β,γ, σ) that describe the unknown normalisation factors,
the mean expression levels in the different groups and the experimental noise. The
Bayesian statistical inference approach combines information from the data D =
{yegjki} with that from prior information using Bayes Theorem, and describes this
through the posterior distribution. If we assume that the prior distribution for each
model parameter can be specified independently, the posterior distribution is
π(κ,α,β,γ, σ|D) ∝
∏
e,(g,i)6=(ge,1)
π(κegi)×
∏
jk
π(αjk)×
∏
g 6=1,j
π(βgj)π(γgj)× π(σ)
× σ−n exp
{
−
1
2σ2
∑
egjki
(yegjki − κegi − αjk − βgjγgj)
2
}
,
where n = EnI
∑
j mj is the total number of log-intensity measurements for the
isobaric labels and π(·) denote prior probability (density) functions.
2.3.1 Prior Distribution on Model Parameters
The Bayesian approach allows for additional information to be incorporated by
using a prior distribution on all model parameters (κ,α,β,γ, σ). Although each
analyst should incorporate their own prior beliefs into the prior distribution, we
have chosen to represent prior beliefs by using standard distributions. This leaves
the analyst to decide on their own choice for the parameters of these distributions.
The prior distributions are, for e = 1, . . . , E, g = 1, . . . , G, j = 1, . . . , P , k =
1, . . . , mj and i = 1, . . . , neg
κegi ∼ N(aκ, 1/bκ), αjk ∼ N(aα, 1/bα),
βgj|pgj ∼ Bern(pgj), pgj ∼ Beta(ap, bp),
γgj ∼ N(aγ , 1/bγ), σ−2 ∼ Ga(aσ, bσ),
where Ga(a, b) is a gamma distribution with mean a/b, Bern(p) is a Bernoulli dis-
tribution with success probability p and Beta(a, b) is a Beta distribution with mean
a/(a + b). The essential model structure over the unknowns is displayed as a plate
diagram in Figure 2.
We suggest the following default choices for the prior parameters. In an
ideal series of experiments, the experimenter uses the same total amount of reporter
in each experiment. In other words, experimenters try to design their experiments so
that the κegi are close to zero. We input this information by taking aκ = 0 and bκ =
1/9. In our experience, log-intensities for reporter ions typically range between
4 and 16 and so taking this range as four standard deviations gives aα = 10 and
bα = 1/9. In most analyses of this kind, the proportion of differentially expressed
proteins will be low, say around 5%. It is possible to undertake the analysis with
this proportion fixed at such a user-specified value. However, as results may be very
sensitive to the value chosen, we prefer to put a prior distribution on the proportion
and learn about it from the data. We suggest taking ap = 1 and bp = 19.
Naturally the degree of differential expression in proteins (relative to the
control group) will vary but we anticipate a typical fold-change to be around one
(zero on the log-scale) and so recommend taking aγ = 0 and bγ = 1. The level
of measurement accuracy of the reporter ion log-intensity measurements is particu-
larly difficult to assess. Therefore we suggest taking a quite weak prior distribution
for σ by using aσ = bσ = 1/1000. Overall we regard these choices of prior param-
eters as inputting relatively weak prior information. Some analysts may feel they
have stronger views to include in their prior distribution and so may feel justified
in taking quite different choices to these “default” ones. We will use our default
choices in the subsequent analyses we present in this paper.
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i=1,...,neg j
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Figure 2: Plate diagram for the essential model structure. The directed acyclic
graph (DAG) over the random variables represents the factorisation of the joint
distribution of unobserved and observed model variables, and is used to construct
posterior inference schemes. Fixed hyperparameters are omitted for clarity.
2.3.2 Posterior analysis
Unfortunately, the posterior distribution is analytically intractable for any signifi-
cant number of proteins and peptides. However, it is possible to simulate realiza-
tions from this distribution by using computer-intensive Markov chain Monte Carlo
(MCMC) techniques; see Gamerman and Lopes (2006). Essentially this algorithm
simulates a Markov chain which has the posterior distribution as its equilibrium
distribution. Thus, after the algorithm has converged (in distribution), all subse-
quent realizations will have the required (posterior) distribution. We have chosen to
implement our model using the free open source software JAGS (Plummer, 2003).
The JAGS code for our model and the key steps in this Gibbs sampling scheme are
given in the appendix. Note that the indexing used in this code is slightly different
to that in (1) to deal with missing data more efficiently: it uses a “ragged array”
structure to avoid creating nodes for missing values. We have found that this fairly
simple one-variable-at-a-time Gibbs updating scheme works very effectively for
this class of models and so more sophisticated MCMC schemes have not been pur-
sued. We have also developed a full R package implementing the model and this is
available as the R-Forge package dpeaqms (dpeaqms, 2011). In more challenging
scenarios, single variable updating schemes for variable selection problems can be
inefficient, and some authors have proposed methods (such as collasping and then
joint updating) which can improve mixing in this case (Bottolo et al., 2010; Davies
et al., 2014). However, such methods are not integrated into off-the-shelf MCMC
engines such as JAGS.
3 Simulated Data Analysis
In order to evaluate the performance of the statistical inference technique outlined
previously, the methods were tested on data simulated from the model (1). The
experimental scenario we consider is one in which there are G = 4 groups consist-
ing of a control group (CTL) and three treatment groups (TRT1, TRT2 and TRT3)
and we have nI = 6 isobaric tags to use. We assume that differential expression
is determined with respect to the control group and so label this as group g = 1;
the other groups TRT1, TRT2 and TRT3 we label as g = 2, 3, 4 respectively. The
simulated dataset we constructed consists of 12 labelled samples and, as this must
have resulted from more than one experiment, we assume that there were E = 2
experiments, with six tagged samples per experiment. We also assumed that overall
there were three samples from each group. The samples were assigned to the six
tag reporter ions according to the pattern (CTL, CTL, TRT1, TRT1, TRT2, TRT2)
for the first experiment and (CTL, TRT1, TRT2, TRT3, TRT3, TRT3) for the sec-
ond experiment. Therefore, the numbers of samples per group in each experiment
are n11 = n12 = n13 = 2, n14 = 0 and n21 = n22 = n23 = 1, n24 = 3. Note
that this experimental design is not as balanced as it might have been, for example,
we could have required at least one sample from each group in each experiment.
However it might not always be possible to construct “balanced” experiments due
to having a large number of groups relative to the number of tags available, and so
we investigate here the effect of using an “unbalanced” experimental design. As we
have a sample from (control) group 1 in each experiment, we take these samples as
the reference samples for the experiments, that is, take g1 = g2 = 1.
We constructed the dataset to contain the results on P = 300 proteins, with
the number of simulated MS/MS spectra per protein (mj) drawn from a geometric
distribution with mean 6, this distribution being chosen to be roughly comparable
with the real MS/MS datasets analyzed in this paper. The mean log-intensities of
the reporter ions for (control) group 1 (αjk) were drawn from a normal distribu-
tion with mean 10 and standard deviation 3.0. Again, this distribution is similar to
those for the real datasets in the paper. The probability of a protein being differen-
tially expressed with respect to the control group CTL was drawn from Bernoulli
distributions with probabilities 0.1, 0.2 and 0.3 for treatment groups TRT1, TRT2
and TRT3 respectively and resulted in 26, 71 and 98 differentially expressed pro-
teins in the treatment groups. We considered fold changes in differential expression
relative to the (control) group varying between 1.5 and 4.0 for up-regulation and
between 1/4.0 and 1/1.5 for down-regulation. This led to us drawing the param-
eters for the level of differential expression (γgj) from a uniform distribution on
(−1.39,−0.41)∪ (0.41, 1.39). The log ratios of the amount of protein in each sam-
ple with respect to a reference sample for each experiment (sample 1 in group ge
of experiment e), the κegi, were drawn from a normal distribution with mean 0 and
standard deviation 0.1. Finally the variability of the errors (σ) was set to 0.3.
The data are summarized in Figure 3, with the left-hand column giving sum-
maries for experiment 1 and the right-hand column for experiment 2. Figures 3(a)
and (b) show histograms of the number of MS/MS spectra per protein for the two
experiments. Clearly the number of proteins decreases as the number of spectra per
protein increases, and is consistent with the simulation model in which the number
of spectra per protein follows a geometric distribution with mean 6. Figures 3(c)
and (d) are box plots of the log-intensities of the reporter ions (labelled by group
and sample within group) in the two experiments. The plots show that there are
no clear differences between groups/samples, with these levels dominated by the
overall mean levels (αjk), which in this simulation have mean 10 and standard de-
viation 3. Figures 3(e) and (f) are MA-plots for two selected samples (sample 1 in
group 2 (TRT1) of experiment 1 and sample 1 in group 4 (TRT3) of experiment 2).
These plots display differences between these samples and the reference sample (in
the corresponding experiment) in the log-intensities (m) against their mean (a) for
each MS/MS spectra in an attempt to highlight any dependence between variability
and overall level in the data. These plots suggest (correctly) that there is no such
dependence in these data.
3.1 Results
We analysed these data using the prior distribution with the default parameter op-
tions and looked at the output of the JAGS code using a variety of initial starting
points. Typically, 10-30K iterations were needed to attain distributional conver-
gence (burn-in) but for the analyses in this paper we adopt a conservative strategy
and use a burn-in of 100K iterations. Note that convergence was assessed by using
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Figure 3: Summary plots for the simulated data: left panel – experiment 1, right
panel – experiment 2. (a) and (b) Histograms of the number of MS/MS spectra per
protein; (c) and (d) Box-plots of the reporter ion log-intensities by group/sample;
(e) and (f) MA-plots for two selected samples (showing the difference in log-
intensities, m, against the average log-intensity, a).
a variety of informal and formal tests. We report here the results from five indepen-
dent runs of the JAGS code in which (after burn-in) each chain was run for a further
100K iterations and thinned by taking every 100th iterate. This gives a total of 5K
(weakly correlated) realizations from the posterior distribution for analysis.
Figure 4 shows kernel density plots for an MCMC sample from the poste-
rior probability distribution for a representative selection of parameters: the mea-
surement error standard deviation σ, four of the normalisation constants κegi and a
log-fold difference in intensity with respect to (control) group 1 βgjγgj for a protein
which was differentially expressed in this group. The vertical dashed lines show the
value used in generating the simulated data. Their location on the posterior plots
verifies that, despite inputting fairly weak prior information, the posterior analysis
has recovered these values reasonably accurately. Note that there is no “spike” at
zero in the posterior density of β2,116γ2,116 because there were no zero values of
β2,116 in the posterior sample.
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Figure 4: Posterior kernel density plots for a selection of parameters: the mea-
surement error standard deviation σ, four of the normalisation constants κegi and a
log-fold difference in intensity with respect to (control) group 1 βgjγgj for a protein
which was differentially expressed in this group. The vertical dashed lines indicate
the value used in generating the simulated data and the dashed curves are the prior
densities used in the analysis.
Table 1 summarises the overall performance of the inference method in
identifying the differentially expressed proteins. Classification is based on a poste-
rior probability of differential expression exceeding 0.5, as is common practice for
Bayesian variable selection problems. In fact the classification is rather insensitive
to the particular choice of probability threshold, since the vast majority of proteins
have posterior probability of differential expression either less than 0.1 or greater
than 0.9. The full distribution of posterior probability of differential expression for
the proteins in each of the 3 treatment groups is summarised in Figure 5. Despite
the relatively high noise level, the method performs quite well for TRT1 and TRT2
but less well for TRT3. On further inspection, we found that the method generally
failed to correctly identify a differentially expressed protein when either the level
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Figure 5: Histograms showing the posterior probability of differential expression
for the proteins in groups TRT1, TRT2 and TRT3, respectively. The vast majority
of proteins in the 3 samples have posterior probability very close to 0 or 1.
Group TRT1 Simulated Simulated
with DE without DE
Inferred as with DE 24 1 25
Inferred as without DE 2 273 275
26 274 300
Group TRT2 Simulated Simulated
with DE without DE
Inferred as with DE 70 0 70
Inferred as without DE 1 229 230
71 229 300
Group TRT3 Simulated Simulated
with DE without DE
Inferred as with DE 87 0 87
Inferred as without DE 11 202 213
98 202 300
Table 1: Performance of the method in detecting differential expression (DE) in
proteins between groups and the control group. Inference for DE is based on a
classification threshold of a posterior probability exceeding 0.5.
of differential expression was small or there were only one or two MS/MS spectra
for the protein in each experiment. Additional complications for TRT3 were due to
its samples only being present in the second experiment.
4 Case Study 1: Dataset on human plasma
Our first case study analyses data from an MS/MS analysis of human plasma pub-
lished in Dayon et al. (2010). The data arise from an experiment to investigate the
use of a particular mass spectrometric technique in the identification and quantifica-
tion of peptides. The experimental design consists of a single experiment (E = 1)
and produced two technically identical samples. We consider these samples to be
single samples (n11 = n12 = 1) from two “artificial” groups (G = 2). Thus, any
differentially expressed proteins will be due to variability in the experimental pro-
cess and the technique used to detect differential expression, and so we expect to
find relatively few proteins that are differentially expressed between the two groups.
The experiment was conducted as follows. After reduction, alkylation and
digestion of the sample with trypsin, two technically identical sub-samples were
taken, labelled with TMT-2plex labels (i.e. nI = 2) and mixed. The resulting
mixture was then run through a liquid chromatograph into a Tandem Mass Spec-
trometer and MS/MS spectra acquired. In this simple experiment, it does not really
matter which group supplies the reference sample. Here, we take this as coming
from group 1, that is, g1 = 1. The MS/MS spectra, in the form of Mascot Generic
Format (MGF) files, were kindly made available for this study by Alexander Scherl.
These were then analysed using Proteome Discoverer version 1.1 (Thermo Fisher
Scientific) and version 3.65 of the IPI sequence database (Kersey et al., 2004). The
list of identified MS/MS spectra was then filtered by requiring them to pass three
criteria: (i) the peptide needed a high identification confidence, with the thresh-
old calculated to give a false discovery rate on the decoy database of 0.01, (ii) the
MS/MS spectra needed to be identified as being those of peptides uniquely deriv-
able from a single protein, and (iii) the MS/MS spectra needed to include both
reporter ion peaks. This left 3158 MS/MS spectra, corresponding to peptides from
P = 94 proteins, for analysis.
Figure 6 gives some summary plots of the data. Figure 6(a) gives a his-
togram of the number of MS/MS spectra per protein. Clearly there are many pro-
teins with only a few spectra and only a few with many spectra. Note that this
shape is consistent with the geometric distribution assumed in the simulation study.
Figure 6(b) gives a box plot of the log-intensities of the reporter ions (labelled by
group and sample within group) and shows no obvious differences between the
groups. Figure 6(c) gives the MA-plot for the two samples. The plot is similar to
those in the simulation study (Figures 3(e) and (f)). Here there is a slight suggestion
of increased variability associated with small measurements, but the effect seems
to be small, and so for the purposes of this analysis we will continue to assume
constant variability.
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Figure 6: Summary plots of the Dayon et al. (2010) human plasma data. (a) His-
togram of the number of MS/MS spectra per protein; (b) Box-plot of the TMT 2-
Plex reporter ion log-intensities by group/sample; (c) MA-plot of the log-intensities
for the two samples (showing the difference in log-intensities, m, against the aver-
age log-intensity, a).
4.1 Results
We now analyse these duplex TMT reporter ion log-intensities and report here the
results from runs of the JAGS code using the procedure described in section 3.1
which give 5K (weakly correlated) realizations from the posterior distribution.
Figure 7 shows summary plots for an MCMC sample from the posterior
probability distribution for a representative selection of parameters: the measure-
ment error standard deviation σ, the (only) normalisation constant κ1,2,1 for the
second sample (g = 2, i = 1) with respect the reference sample (g = 1, i = 1)
and the log-fold difference in intensity β2,62γ2,62 for protein IPI00647704 with re-
spect to (control) group 1. This protein was chosen as it has the highest posterior
probability of being differentially expressed. The trace and auto-correlation plots
are typical of all five chains and suggest that there are no mixing problems and that
convergence has been attained.
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Figure 7: Results for an analysis of the data in Dayon et al. (2010): trace and auto-
correlation plots from a single chain and the posterior kernel density plot from all
five chains for a representative selection of parameters: the measurement error stan-
dard deviation σ, the log-normalisation parameter κ1,2,1 and the product β2,62γ2,62
for protein IPI00647704.
Means of the posterior output for the differential expression indicator pa-
rameters βgj can be used to estimate the posterior probability of differential ex-
pression for each protein. Of the 94 proteins examined, only two had a posterior
probability exceeding 0.1. These were IPI00647704 and IPI00916434, with poste-
rior probabilities 0.8 and 0.3 respectively. If we assume that the two samples were
perfect technical replicates, then using a posterior probability threshold of 0.5 to
declare whether or not proteins are differentially expressed gives a false positive
rate around 1%.
A natural part of any data analysis is to assess the validity of the model used
to make inferences. We favour checks using the posterior predictive distribution
of the (logged) intensities, that is, their distribution allowing for the posterior un-
certainty in the model parameters; see Gelman et al. (2003), Chapter 6 for details.
The posterior predictive density is straightforward to determine using the MCMC
output {κ(ℓ)egi, α
(ℓ)
jk , β
(ℓ)
gj , γ
(ℓ)
gj , σ
(ℓ); ℓ = 1, . . . , N} for our model as
f (yegjki) ≃
1
N
N∑
ℓ=1
φ
(
yegjki − (κ
(ℓ)
egi + α
(ℓ)
jk + β
(ℓ)
gj γ
(ℓ)
gj )
σ(ℓ)
)
.
A useful diagnostic of model fit can be based on the location of the observed inten-
sities within their individual predictive distributions as a well fitting model will pro-
duce posterior predictive distributions consistent with the observed log-intensities.
Figure 8 shows histograms of samples from the posterior predictive densities for
a random selection of nine observed log-intensities. These show that the model
provides a good fit to the data (shown in red).
It is interesting to compare our results with those obtained by using existing
methods: a t-test and a moderated t-test (Smyth, 2004), both using log intensity
data, as in our Bayesian analysis. Since the t-test looks at differences between pep-
tide intensities (on the log scale), the normalisation constant for specific peptides
(corresponding to α in the Bayesian model) drops out of the analysis, and therefore
does not require explicit normalisation. However, the normalisation constant asso-
ciated with the sample (corresponding to κ in the Bayesian model) does not drop
out, and therefore the raw log intensities must be pre-processed in order to apply
sample normalisation before the t-test can be carried out. Here we normalise each
sample by its mean value. This is one of the standard normalisation techniques com-
monly used, and is the method most directly comparable to our Bayesian model.
Including the normalisation constants explicitly in the model has the advantage that
it allows direct modelling of the experimental data. Our approach to modelling
normalisation constants is similar to the approach used by Oberg et al. (2008) in a
frequentist context. For these data, both the t-test and the moderated t-test suggest
that there are no differentially expressed proteins at the 5% significance level after
using an FDR correction for testing multiple hypothesis (Benjamini and Hochberg,
1995). It is worth noting that the pre-normalisation step is necessary, and that differ-
ent methods of normalisation can lead to different results (Karpievitch et al., 2012).
By contrast, the Bayesian model-based method developed here includes normal-
ization constants explicitly as part of an integrated model and so normalizing the
data prior to analysis is not required. We have also found that our method is rela-
tively insensitive to whether or not the data have been preprocessed using standard
normalization methods.
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Figure 8: Histograms showing the posterior predictive distributions for a random
selection of observed log-intensities (uniquely identifiable by experiment e, pro-
tein j, MSMS spectra k and sample gi). The red vertical line shows the observed
log-intensity.
5 Case Study 2: ProteoRed multi-centric experiment 5
Our second case study analyses data from an experiment carried out by the Proteo-
Red consortium as part of an assessment of various quantitative proteomics meth-
ods. The experiment analysed a mixture of E. coli proteins. The mixture was pre-
pared by fractionation of the cytoplasmic proteome of E. coli and contained soluble
proteins with a wide range of values for the isoelectric point (pI, the pH at which a
molecule carries no net electrical charge) and average molar mass (Mw).
After dividing the mixture into two identical portions A and B, four xenobi-
otic proteins were added into the portions in differing amounts. The aim of this re-
search was to evaluate the performance of different proteomics methods by observ-
ing their ability to detect the existence of the xenobiotic proteins within the other-
wise identical samples/portions. The xenobiotic proteins used were CYC HORSE
(Cytochrome C, Mw 12362), MYG HORSE (Apomyoglobin, Mw 16952), AL-
DOA RABIT (Aldolase, Mw 39212) and ALBU BOVIN (Serum albumin, Mw
66430) and their (theoretical) differential expression between the two portions is
given in Table 2.
Code Protein Ratio (B/A) log(B/A)
CYC Horse Cytochrome C 1.50 0.4055
MYG Horse Apomyoglobin 0.38 −0.9676
ALDOA Rabbit Aldolase 0.50 −0.6931
ALBU Bovine Serum Albumin 5.00 1.6094
Table 2: Theoretical ratios of xenobiotic proteins in portions A and B
The experiment produced data by using a TMT-6plex (nI = 6) labelling of
three technical replicate sub-samples of each of the two portions. Sub-samples in
portion A were labelled with even TMT-6plex labels (TMT126, TMT128, TMT130)
and, in portion B, labelled with odd TMT-6plex labels (TMT127, TMT129, TMT131).
The resulting labelled sub-samples were then mixed and the mixture divided into
two technically identical portions. Each of these portions was then subjected to
independent MS/MS analyses. In terms of our model, this gives an experimental
design consisting of E = 2 experiments and G = 2 groups, and we label por-
tion A as group 1 and portion B as group 2. The numbers of replicates in each
experiment×group are n11 = n12 = n21 = n22 = 3. The reference sample was set
to its default in both experiments (g1 = g2 = 1).
We obtained the MS/MS peak list as an MGF file for both of the analyses.
These were then analysed using Proteome Discoverer v.1.1 (Thermo Fisher Sci-
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Figure 9: Summary plots for the ProteoRed data: left panel – experiment 1, right
panel – experiment 2. (a) and (b) Histograms of the number of MS/MS spectra per
protein; (c) and (d) Box-plots of the reporter ion log-intensities by group/sample;
(e) and (f) MA-plots for two selected samples (showing the difference in log-
intensities, m, against the average log-intensity, a).
entific) and the current version of the UniProt sequence database for E. coli (Jain
et al., 2009). The list of identified peptides was then filtered to retain only those
peptides with a high identification confidence, with the threshold calculated to give
a false discovery rate on the decoy database of 0.01, and which were proteotypic.
Also MS/MS spectra which did not have complete quantitative information for the
six labels were excluded from the analysis. This left 238 and 259 proteins, each
with at least one fully quantified MS/MS spectra, for the analyses of portions A
and B respectively. In total, the two analyses provided quantitative information for
282 proteins. The data are summarised in Figures 9 and 10. Figures 9(a) and (b)
shows histograms of the number of MS/MS spectra per protein for each experiment.
As with the first case study, these distributions are consistent a geometric distribu-
tion. Figures 9(c) and (d) are box plots of the log-intensities of the reporter ions
(labelled by group and sample within group), and panels (e) and (f) show MA plots
for two of the samples. All of the plots suggest that the data is consistent with the
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Figure 10: Box-plots of the reporter ion log-intensities by group for the four spiked
in proteins: left panel – experiment 1, right panel – experiment 2.
assumptions of our model.
5.1 Results
We now analyse the ProteoRed dataset and, as with the previous analyses, base our
analysis on the 5K realizations from the posterior distribution obtained by using the
procedure described in section 3.1.
The analysis clearly identified all four spiked-in proteins as being differen-
tially expressed, each with a posterior probability exceeding 0.999. The posterior
distribution of the log ratio log(B/A) for each spiked protein is shown in Figure 11.
Comparing these distributions with the theoretical values given in Table 2, we see
that the values of the distributions for three of the four spiked proteins are of the
right order of magnitude. Unfortunately, the analysis gives a posterior ratio for the
ALBU (Bovine Serum Albumin) spiked protein which is out by a factor of more
than 3. Other analyses of this dataset have come to similar conclusions (see results
section in ProteoRed (2010)) and we suspect this is due to contamination in the
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Figure 11: Posterior kernel density plots for the log ratio log(B/A) of the spiked
proteins MYG, ALDOA, CYC and ALBU. The vertical dashed line shows the the-
oretical value for the log ratio.
original sample or at some stage in the preparation of the samples for the MS/MS
experiment. Whatever the reason, this has clearly affected the estimation of the
ratios for all the spiked proteins.
The analysis also identified four other (non-spiked) E. coli proteins as be-
ing differentially expressed when using a posterior probability threshold of 0.5:
three main ones A7J0Q2, C3SFD7 and P02754 with posterior probabilities exceed-
ing 0.999 and C3SVU2 with posterior probability 0.52. Nearly all of the remaining
E. coli proteins (271 of the remaining 274) had a posterior probability of being dif-
ferentially expressed below 0.05. As in the analysis of the dataset in section 4, we
assessed model fit by comparing the observed data with their posterior predictive
distributions and this confirmed that the model provided a reasonable fit to the data.
As before, we now compare the results of our analysis with those deter-
mined by using a standard t-test and by using a moderated t-test together with an
FDR multiple hypotheses correction. Again, we follow standard practice and pre-
normalise the data so that the sample means are the same. For both test-based
analyses, the spiked proteins were found to be significantly differentially expressed
(q ≤ 10−6). These analyses also found false positives, with the t-test analysis and
the moderated t-test analysis identifying an additional ten and seven non-spiked
proteins respectively (q ≤ 0.05).
6 Discussion
In this paper we developed a model based approach to solving a general problem in
quantitative proteomics using mass spectrometric (MS/MS) methods with isobaric
labelling. The problem is that of determining which, if any, of a set of proteins in
a complex mixture are differentially expressed between two or more groups and if
so to quantify the degree of differential expression. This is not straightforward to
resolve given the inherently stochastic nature of mass spectrometric data. Further
complications are introduced, given that the protein intensities are not measured
directly. What is observed are the intensities of the isobaric labels for the peptides
resulting from enzyme digestion (usually trypsin) of these proteins.
The model based approach allows us to integrate data from multiple MS/MS
experiments into a single statistical inference framework. An important feature of
our framework is that these experiments do not have to be simple replicate experi-
ments. This allows us to design a set of isobaric labellings that expands the effective
number of samples (and therefore biological groups) that can be analysed beyond
the maximum of eight isobaric labels which is currently commercially available
(Choe et al., 2007). This ability to integrate data is a distinct advantage not offered
by more standard approaches. Previous work by Hill et al. (2008) also uses a model
based approach and makes this very point about combining data from multiple ex-
periments. However, we use a more flexible and, we believe, more intuitively inter-
pretable Bayesian statistical approach to inferring model parameters, whereas they
use an ANOVA-based approach. An additional advantage of the Bayesian approach
is that we can make direct inferences for the probability of differential expression,
and so there is no need to correct for multiple hypotheses, as would be required for
the ANOVA approach, for example, in order to determine whether protein ratios
differed significantly from one.
A common concern with Bayesian analyses can be that results are sensitive
to the choice of prior distribution parameters. In order to assess whether our results
were robust and not an artifact of the prior choice, we investigated using a wide
range of different values of the parameters of the priors. We found that the results
for differentially expressed proteins were very robust for different prior choices
for τ and κ. The results are slightly more sensitive to the prior choices for the
distribution on pgj , the prior probability of protein j in group g being differentially
expressed. Sensitivity to the prior on variable inclusion is a well-known issue in
Bayesian variable selection (O’Hara and Sillanpaa, 2009).
In order to evaluate the method developed here we apply the technique to
two MS/MS datasets. First the performance of the method was evaluated on a
negative control. This is a dataset which we know should have no differentially ex-
pressed proteins. The dataset was from an MS/MS analysis of two technical repli-
cate samples of human plasma labelled with a 2-plex TMT reagent. For this dataset
we can reasonably assume that none of the proteins are differentially expressed. Of
the 94 proteins identified from the data only a single protein was inferred as having
a ≥ 0.5 mean posterior probability of being differentially expressed with a value of
0.815. This corresponds to an acceptably low false positive rate.
The second dataset was data from an MS/MS analysis of a sample used in
a ProteoRed group experiment. The data consisted of technical replicates of an
E. coli cytoplasmic proteome sample (A and B). These were spiked with differing
amounts of four xenobiotic proteins. This acted as our positive control since the
spiked proteins and their relative amounts are known. Again the method developed
here was able to infer that the spiked proteins were differentially expressed with a
high probability. The degree differential expression for these proteins was also of
the right order for three of the proteins but was off by a factor > 3.0 for the Bovine
Serum Albumin (ALBU) protein. Four out of the 278 non-spiked proteins were also
inferred as differentially expressed: three with a high probability (> 0.999) and one
with a borderline probability of 0.52.
In conclusion, our Bayesian statistical inference approach to determining
differentially expressed proteins from isobaric labelled MS/MS data has been found
to perform well on a variety of real and simulated datasets. The modelling frame-
work allows us to perform a unified statistical analysis of multiple experiments and
the multiple hypotheses are integrated into the model itself so there is no need for
ad hoc normalisation methods or multiple hypothesis corrections. The model al-
lows comparison of multiple experiments within a single unified model, thereby
extending the range of applicability of the isobaric labelling technology. Impor-
tantly the model has a variable selection form which ensures that we fit an appro-
priate model for the combination of differentially expressed and non-differentially
expressed proteins. Models without this structure have the drawback that they in-
flate the error variance in the “null” model due to contamination by outlying dif-
ferentially expressed proteins which then hinders the detection of differential ex-
pression. A unified analysis approach using a frequentist ANOVA analysis has
previously been described by Oberg et al. (2008). Fortunately, missing data is less
of an issue when analysing isobaric labelled samples in MS/MS experiments than it
is for other proteomic technologies, such as LC–MS. Nevertheless, missing values
are often present in data sets, and this can complicate frequentist analysis consid-
erably. However, adopting a Bayesian approach is helpful in that it allows us to
marginalise the model over any missing data as a routine part of the analysis. It
would be relatively straightforward to extend our model to cover informative miss-
ingness, but we believe that our current model captures the most important sources
of variation in typical labelled MS/MS datasets. Finally, the results we obtain are
intuitively interpretable through simple probabilities of the analysed proteins being
differentially expressed.
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Appendix
The JAGS model implementing the differential protein expression model described
in section 2.2 is shown below.
model {
Tau ˜ dgamma(a.tau,b.tau)
Sigma <- 1/sqrt(Tau)
for (j in 1:P) {
for (k in 1:m[j]) {
Alpha[moffset[j]+k] ˜ dnorm(a.alpha,b.alpha)
}
}
for (e in 1:E) {
kappa[e,1] <- 0
for (s in 2:numberOfSamples[e]) {
kappa[e,s] ˜ dnorm(a.kappa,b.kappa)
}
}
for (j in 1:P) {
p[1,j] <- 0.0
Beta[1,j] <- 0.0
Gamma[1,j] <- 0.0
for (g in 2:G) {
p[g,j] ˜ dbeta(a.p,b.p)
Beta[g,j] ˜ dbern(p[g,j])
Gamma[g,j] ˜ dnorm(a.gamma,b.gamma)
}
for (n in 1:N[j]) {
intensity[offset[j]+n] ˜ dnorm(kappa[experiment[offset[j]+n],
sample[offset[j]+n] - sampleoffset[experiment[offset[j]+n]]]
+ Alpha[peptide[offset[j]+n]]
+ Beta[group[offset[j]+n],j]*Gamma[group[offset[j]+n],j]
,Tau);
}
}
}
Package Installation and Getting Started
The dpeaqms package is an R package which relies on the rjags package and the na-
tive JAGS library already being installed. The JAGS library can be downloaded and
installed from http://www-ice.iarc.fr/
˜
martyn/software/jags/.
The rjags package is an R interface to this native JAGS library and can be installed
within R by using the command
install.packages("rjags")
and then the dpeaqms package can be installed by using the command
install.packages("dpeaqms",
repos="http://r-forge.r-project.org")
Once the dpeaqms package is installed, an overview vignette can be accessed by
using the command
vignette("dpeaqms")
A vignette showing the analysis of the simulated dataset described in section 3 can
be accessed using the command
vignette("dpeaqms.simulatedDataset")
The MCMC sampling scheme
The MCMC scheme is a Gibbs sampler which involves simulating realisations of
the model parameters in turn from their full conditional distributions as follows:
• The log-normalisation ratio for reporter ion i in experiment e is simulated
using κegi|· ∼ N(Aegi, 1/B) for (g, i) 6= (ge, 1), where
Aegi =
aκbκ +
∑
jk(yegjki − αjk − βgjγgj)/σ
2
bκ + nκ/σ2
, Bei = bκ + nκ/σ
2,
and nκ =
∑
j mj is the number of log-intensity measurements for reporter i
in experiment e.
• The mean log-expression level for MS/MS spectrum k for (control) group 1
is simulated using αjk|· ∼ N(Cjk, 1/D), where
Cjk =
aαbα +
∑
egi(yegjki − κegi − βgjγgj)/σ
2
bα + nα/σ2
, D = bα + nα/σ
2,
and nα =
∑
eg neg is the number of log-intensity measurements for each mass
spectrum k assigned to protein j.
• The parameter βgj (g 6= 1) indicating whether or not the protein j is differen-
tially expressed for group g with respect to control group 1 is simulated using
probabilities
π(βgj = 0|·) ∝ (1− pgj) exp
{
−
1
2σ2
∑
eki
(yegjki − κegi − αjk)
2
}
,
π(βgj = 1|·) ∝ pgj exp
{
−
1
2σ2
∑
eki
(yegjki − κegi − αjk − γgj)
2
}
.
• The probability of differential expression of a protein j in group g is simulated
using pgj|· ∼ Beta(ap + βgj, bp + 1− βgj) for g 6= 1.
• The difference in the mean log-expression levels of protein j between group
g ( 6= 1) and the control group is simulated using γgj|βgj = 0, · ∼ N(aγ , 1/bγ),
its prior distribution, or γgj|βgj = 1, · ∼ N(Egj , 1/Fgj) as appropriate, where
Egj =
aγbγ +
∑
eki (yegjki − κegi − αjk) /σ
2
bγ + n
γ
gj/σ
2
, Fgj = bγ + n
γ
gj/σ
2
and nγgj = mj
∑
e neg is the total number log-intensities measurements for
samples in group g for protein j.
• The error standard deviation is simulated using σ−2|· ∼ Ga (aσ + n/2, bσ +G/2)
where G =
∑
egjki(yegjki− κegi−αjk − βgjγgj)
2 and n = EnI
∑
j mj is the
total number of log-intensity measurements for the isobaric labels.
